drugset / Trial / NCT02744664

Cryotherapy Combine Icotinib for Advanced NSCLC Treatment

NCT02744664

Phase 4 Completed 60 enrolled Fuda Cancer Hospital, Guangzhou
NaSingle-groupOpen-labelTreatment

Summary

This trial is to designed to assess the efficacy and safety of Cryotherapy combine with Icotinib for Advanced NSCLC Patients harboring EGFR mutation.

Timeline

Start
2016-04-01
Primary completion
2017-08-15
Completion
2017-08-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Icotinib Small molecule 125 mg Oral

Indications